Current guidelines for heparin-induced thrombocytopenia (HIT) management recommend
heparin cessation and switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) …

Despite the availability of multiple nonheparin anticoagulants for the treatment of heparin-
induced thrombocytopenia (HIT), few data are available comparing the cost-effectiveness of …

Background: Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the
alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid. Frequently, the …

Background Fondaparinux is commonly used for treatment of heparin‐induced
thrombocytopenia (HIT) despite lack of approval for this indication. High quality randomized …

Introduction In life-threatening immune heparin-induced thrombocytopenia (HIT), treatment
with an approved non-heparin anticoagulant is essential. However, off-label use with …

Objective: To review the available literature addressing the role of fondaparinux in the
management of heparin-induced thrombocytopenia (HIT). Data Sources: Primary articles …

Fondaparinux is a synthetic antithrombin-binding" penta-saccharide" anticoagulant with
proven antithrombotic efficacy in a variety of prophylactic and therapeutic settings (1) …

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic condition and adverse drug
reaction caused by immunoglobulin G (IgG) antibodies directed against the heparin-platelet …

Heparin-induced thrombocytopenia (HIT) is a life-threatening immune response to heparin
that is associated with a high risk of thromboembolic complications. The syndrome is caused …

Objective: TO review literature evaluating the use of fondaparinux for thromboembolic
treatment and prophylaxis in patients with heparin-induced thrombocytopenia (HIT). Data …